Ultragenyx Pharmaceutical (NASDAQ:RARE) announced its earnings results on Tuesday. The biopharmaceutical company reported ($1.89) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.96) by $0.07, Briefing.com reports. During the same quarter last year, the business earned ($1.75) EPS.
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded up $1.06 during midday trading on Tuesday, reaching $48.18. 797,238 shares of the company traded hands, compared to its average volume of 674,781. Ultragenyx Pharmaceutical has a fifty-two week low of $41.67 and a fifty-two week high of $91.35. The firm has a market capitalization of $2,260.00, a price-to-earnings ratio of -6.91 and a beta of 1.89.
A number of equities analysts have recently issued reports on the stock. BidaskClub lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, February 9th. Zacks Investment Research lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an “in-line” rating to an “outperform” rating in a research report on Monday, January 22nd. Credit Suisse Group assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, January 17th. They set an “outperform” rating and a $67.00 target price on the stock. Finally, Raymond James Financial reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Friday, December 15th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $72.06.
COPYRIGHT VIOLATION WARNING: “Ultragenyx Pharmaceutical (RARE) Releases Earnings Results, Beats Estimates By $0.07 EPS” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/21/ultragenyx-pharmaceutical-rare-releases-earnings-results-beats-estimates-by-0-07-eps.html.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.